OHKURI Takayuki

オオクリタカユキ | OHKURI Takayuki

Affiliation and department：
Job title： Associate Professor

Research field (5)： Medical biochemistry , Experimental pathology , Human pathology , Tumor diagnostics and therapeutics , Immunology

Research keywords (3)： Stealth antigens , DAMPs , Tumor immunology

Research theme for competitive and other funds (11)：

Show all

Papers (62)：

Risa Wakisaka, Hidekiyo Yamaki, Michihisa Kono, Takahiro Inoue, Ryosuke Sato, Hiroki Komatsuda, Kenzo Ohara, Akemi Kosaka, Takayuki Ohkuri, Toshihiro Nagato, et al. Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer. Cancers. 2024. 16. 17
Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Ryusuke Hayashi, Takumi Kumai, Hidekiyo Yamaki, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, et al. Immunotherapy targeting tumor-associated antigen in a mouse model of head and neck cancer. Head & neck. 2024
Toshihiro Nagato, Hiroki Komatsuda, Ryusuke Hayashi, Miki Takahara, Nanami Ujiie, Akemi Kosaka, Takayuki Ohkuri, Kensuke Oikawa, Ryosuke Sato, Risa Wakisaka, et al. Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma. Cancer science. 2024
Aiko Murai, Terufumi Kubo, Takayuki Ohkuri, Junko Yanagawa, Yuki Yajima, Akemi Kosaka, Dongliang Li, Toshihiro Nagato, Kenji Murata, Takayuki Kanaseki, et al. NF9 peptide specific cytotoxic T lymphocyte clone cross react to Y453F mutation of SARS-CoV-2 virus spike protein. Immunological medicine. 2024. 1-7
Yuki Yajima, Akemi Kosaka, Takayuki Ohkuri, Yoshihiko Hirohashi, Dongliang Li, Takeshi Nagasaki, Toshihiro Nagato, Toshihiko Torigoe, Hiroya Kobayashi. SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity. Heliyon. 2023. 9. 9

ｍore...

MISC (2)：

大栗敬幸, 野口大輔, 小林稔, 増子和尚, 大竹淳矢, 脇田大功, 茶本健司, 富樫裕二, 北村秀光, 西村孝司. 新規Survivinヘルパーペプチドの同定と免疫不全マウスを用いたSurvivin特異的Th1細胞による抗腫瘍効果の検討(Identification of novel helper epitopes of Survivin and antitumor effects of human Th1 cells in immunodeficient mice). 日本癌学会総会記事. 2009. 68回. 287-287
大栗敬幸, 野口大輔, 小林稔, 増子和尚, 大竹淳矢, 脇田大功, 茶本健司, 北村秀光, 富樫裕二, 西村孝司. 抗腫瘍エフェクター細胞新規Survivin由来ヘルパーペプチドの同定と免疫不全マウスを用いたTh1細胞治療モデルの確立. 日本がん免疫学会総会プログラム・抄録集. 2009. 13回. 62-62

Patents (2)：

Lectures and oral presentations (10)：

自然免疫が主導するがん特異的T細胞応答の誘導
(2024年がん関連三学会 Rising Star ネットワーキング 2024)
自然免疫が主導する組織炎症と獲得免疫の誘導
(第124回北海道癌談話会シンポジウム 2022)
がん免疫サイクルの駆動力となる自然免疫
(第26回日本がん免疫学会総会 2022)
乳がん組織におけるマクロファージとCD47-新しいがん免疫治療法の糸口
(第110回日本病理学会総会 2021)
Targeting tumor-specific helper T-cells and stimulator of interferon genes for cancer immunotherapy
(第78回日本癌学会学術総会 2019)

ｍore...

Education (3)：

2005 - 2009 Hokkaido University Graduate School of Medicine
2003 - 2005 Hokkaido University Graduate School of Medicine Division of Medical Sciences
1999 - 2003 Hokkaido University School of Science

Work history (6)：

Show all

Committee career (2)：

Awards (5)：

Association Membership(s) (5)：

日本生化学会 , AACR , 日本病理学会 , 日本がん免疫学会 , 日本癌学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page